Innoviva Inc (HVE.BE)
- Business Wire
Innoviva to Participate in Upcoming Investor Conferences
BURLINGAME, Calif., September 04, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:
- Associated Press Finance
Innoviva: Q2 Earnings Snapshot
BURLINGAME, Calif. AP) — Innoviva Inc. INVA) on Wednesday reported a loss of $34.7 million in its second quarter.
- Business Wire
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif., July 31, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2024, and highlighted select corporate achievements.
